Zealand Pharma to accelerate drug development for obesity, metabolic disease
LONDON, Dec 11 (Reuters) - Danish biotech company Zealand Pharma ZELA.CO said on Thursday it will accelerate development and expand its research as it seeks to differentiate its experimental obesity drug candidates in an increasingly competitive race to treat metabolic health issues. (Reporting by Maggie Fick and Terje Solsvik, editing by Essi Lehto) ((maggie.fick@thomsonreuters.com; +44 7890 916706;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)